

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhaoke Ophthalmology Limited
兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

**VOLUNTARY ANNOUNCEMENT –
ENTERED INTO A DEFINITIVE AGREEMENT
FOR THE ACQUISITION OF THE GLOBAL RIGHTS TO
NVK002 (ATROPINE SULFATE EYE DROPS)**

This announcement is made by the board of directors (the “**Board**”) of Zhaoke Ophthalmology Limited (the “**Company**”) on a voluntary basis.

The Board of the Company is pleased to announce that, on June 22, 2026, the Company has acquired global rights to NVK002 (Atropine Sulfate Eye Drops), a product designed to slow the progression of myopia in children.

Under the terms of the agreement, the Company will obtain worldwide ownership of all intellectual property, trademarks, regulatory filings, clinical data, manufacturing capabilities, and other related assets associated with NVK002. This acquisition grants the Company full control over the product’s development, manufacturing, and commercialization worldwide. The agreement supersedes the Company’s existing license arrangement, consolidating rights under the Company’s ownership and enabling streamlined global strategy execution.

As part of the transaction, the Company granted a perpetual, royalty-free, exclusive license to the seller of NVK002, which right was assigned to Nevakar Pharmaceuticals, Inc., (“**Nevakar**”) to develop and commercialize NVK002 in the United States.

Nevakar will support a transition period and remain a strategic partner in the U.S. market. The agreement also contains standard clauses relating to non-compete obligations, regulatory cooperation and indemnification, so as to safeguard operational continuity and protect asset value.

ABOUT ATROPINE SULFATE EYE DROPS (NVK002)

Atropine Sulfate Eye Drops (NVK002) adopts a proprietary formulation that effectively resolves the instability of low-concentration atropine. This technology is protected by intellectual property rights globally. The eye drops are preservative-free with a 24-month shelf life.

ABOUT THE PRIOR LICENCE AGREEMENT

In October 2020, the Company entered into a license agreement, namely the NVK002 License Agreement, with Nevakar, for an exclusive license to develop, manufacture, register, import and commercialize NVK002 in Greater China, South Korea and certain countries in Southeast Asia (including Brunei, Burma, Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand and Vietnam).

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately develop, or commercialize Atropine Sulfate Eye Drops successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, July 13, 2026

As at date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as Executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.